imiquimod has been researched along with diphenylcyclopropenone in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hengge, UR; Meykadeh, N | 1 |
| Burkhart, CN; Dasher, DA; Morrell, DS | 1 |
| Borowska, K; Wasyłyszyn, T | 1 |
| Fabi, SG; Zaleski-Larsen, LA | 1 |
| Grimes, PE; Nashawati, R | 1 |
| Read, T; Schaider, H; Smithers, BM; Soyer, HP; Thomas, J; Wagels, M; Webber, S | 1 |
| Abadir, W; Alavi, N; Look Hong, NJ; Nadler, A; Wright, FC | 1 |
| Díaz-Guimaraens, B; Dominguez-Santas, M; Hermosa-Gelbard, Á; Moreno-Arrones, ÓM; Saceda-Corralo, D; Suarez-Valle, A; Vañó-Galván, S | 1 |
3 review(s) available for imiquimod and diphenylcyclopropenone
| Article | Year |
|---|---|
Immunotherapy for childhood warts.
Topics: Adjuvants, Immunologic; Aminoquinolines; Antigens; Child; Child, Preschool; Cimetidine; Cyclobutanes; Cyclopropanes; Dinitrochlorobenzene; Histamine H2 Antagonists; Humans; Imiquimod; Immunotherapy; Injections, Intralesional; Irritants; Treatment Outcome; Warts | 2009 |
Laser-Assisted Drug Delivery.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Aminolevulinic Acid; Aminoquinolines; Analgesics; Antibodies; Antineoplastic Agents; Ascorbic Acid; Cyclopropanes; Dermatologic Agents; Drug Delivery Systems; Fluorouracil; Humans; Imiquimod; Immunotherapy; Laser Therapy; Methotrexate; Minoxidil; Permeability; Photosensitizing Agents; Polyesters; RNA, Small Interfering; Skin; Timolol; Vaccines | 2016 |
Depigmentation Therapies for Vitiligo.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anisoles; Body Surface Area; Cryotherapy; Cyclopropanes; Humans; Hydroquinones; Imatinib Mesylate; Imiquimod; Low-Level Light Therapy; Patient Selection; Phenol; Protein Kinase Inhibitors; Severity of Illness Index; Skin Lightening Preparations; Vitiligo | 2017 |
1 trial(s) available for imiquimod and diphenylcyclopropenone
| Article | Year |
|---|---|
Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Clinical Protocols; Cyclopropanes; Female; Humans; Imiquimod; Immunotherapy; Male; Melanoma; Middle Aged; Pilot Projects; Remission Induction; Research Design; Skin Neoplasms; Treatment Outcome; Young Adult | 2017 |
4 other study(ies) available for imiquimod and diphenylcyclopropenone
| Article | Year |
|---|---|
[Topical immunomodulators in dermatology].
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Asthma; Autoimmune Diseases; Bowen's Disease; Child; Cyclopropanes; Dermatitis, Atopic; Dinitrochlorobenzene; Female; Follow-Up Studies; Herpes Simplex; Humans; Imidazoles; Imiquimod; Immunity, Cellular; Immunocompromised Host; Immunoglobulin A; Immunosuppressive Agents; Lichen Sclerosus et Atrophicus; Male; Molluscum Contagiosum; Papillomavirus Infections; Precancerous Conditions; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Time Factors; Warts | 2003 |
Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Alopecia Areata; Aminoquinolines; Child; Cyclopropanes; Drug Therapy, Combination; Female; Humans; Imiquimod; Male; Photosensitizing Agents; Retreatment; Young Adult | 2017 |
Lesional therapies for in-transit melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopropanes; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate | 2020 |
Imiquimod-enhanced immunotherapy with diphencyprone for patients with alopecia areata.
Topics: Adult; Alopecia Areata; Cyclopropanes; Dermatitis, Contact; Female; Hair; Humans; Imiquimod; Immunologic Factors; Immunotherapy; Male; Treatment Outcome | 2022 |